Analysis of domestic availability and market sales prospects of Tarlatamab-Imdelltra in 2025

Tarlatamab (trade name: Imdelltra) is a novel bispecific T cell-redirecting antibody for the treatment of small cell lung cancer (SCLC). Its mechanism of action is to simultaneously target tumor-associated antigens and T cellsCD3 receptors, guiding T cells directly to tumor cells to achieve precise immune killing. This innovative mechanism enables talatumumab to demonstrate good clinical potential in the treatment of patients with relapsed or refractory small cell lung cancer.

In terms of domestic availability, talatumumab has not yet been officially launched, but a marketing application has been submitted to the China State Food and Drug Administration in 2025, which means that domestic patients are expected to have legal purchasing channels in the future. Because it has not yet been approved, domestic hospitals and pharmacies are temporarily unable to provide the drug, and it cannot be included in medical insurance reimbursement, which poses certain restrictions on patient accessibility. If patients need to use it, they need to obtain it through clinical trials or formal overseas channels. At the same time, they should pay attention to the legality and safety of the source of the drug.

From the perspective of overseas markets, talatumumab has been approved by the U.S. FDA in 20245 months, and the specifications are < span>1mg and 10mg are priced at approximately 25,000 yuan and 148,000 yuan respectively. There are currently no relevant generic drugs on the market, and prices are relatively high, which means that even if they are launched domestically, the cost of the drug may still be a focus of concern for patients and medical institutions in the short term. In the domestic market, if approved, the drug price may be affected by multiple factors such as policy, exchange rate, and import costs. At the same time, whether the drug is included in medical insurance will also directly affect the patient's out-of-pocket ratio.

From the perspective of market prospects, talatumumab, as a new targeted immune drug for small cell lung cancer, has filled the treatment gap for relapsed or refractory patients. Considering the large number of patients with small cell lung cancer in China and the limited existing treatment options, its potential in the domestic market is huge. With the accumulation of clinical usage data and the development of more indication studies, it is expected that talatumumab will gradually become an important treatment option for high-risk and relapsed patients in the future, but price and medical insurance policies will still be key factors affecting its promotion.

Reference materials:https://www.drugs.com/